Moreover, Roberts et al. reported that ejaculate-derived hepsin, PCA3, and miRNA, together with serum PSA, represented a better predictor of the status and risk of prostate cancer than PSA alone [79], showing the improved diagnostic and prognostic value of the use of a combination of different types of ejaculate biomarkers together with serum PSA. This evidence concerns the gene HPN and prostate cancer.